company history

Fiplate is the distribution Company for Fibrinogen-S. The success of Fibrinogen-S is the result of 33 years of research conducted by Dr. Yen, using the inventor's own savings.

Work conducted independently at a leading University has confirmed a 40% survival rate in mice exposed to lethal doses of irradiation who are treated with Fibrinogen-S, due to less internal bleeding; this is compared to the control group of 0% survival. As a result, the National Institute of Health has awarded the private institution a contract to expand on the work, which will include studying the beneficial effects of Fibrinoplate-S on radiation-induced thrombocytopenia in non-human primates.